Ripasudil (also known as K115) is currently in clinical use as a topical treatment for glaucoma and ocular hypertension37,38 and is a more selective inhibitor of ROCK2 with IC50 of 0.051 μM for ROCK1 and 0.019 μM for ROCK239. Here, ROCK2 is linked to glaucoma.